- Home
- DTF vs SERA Comparison
DTF vs SERA Comparison
Compare DTF & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTF | SERA |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 90.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DTF | SERA |
|---|---|---|
| Price | $11.34 | $3.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.1K | ★ 36.9K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $95,000.00 |
| Revenue This Year | N/A | $217.92 |
| Revenue Next Year | N/A | $479.25 |
| P/E Ratio | $24.34 | ★ N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $10.29 | $1.37 |
| 52 Week High | $11.19 | $9.13 |
Technical Indicators
Market Signals| Indicator | DTF | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 45.38 |
| Support Level | $11.27 | $2.81 |
| Resistance Level | $11.35 | $3.56 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 52.12 | 28.29 |
Price Performance
Historical ComparisonAbout DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.